DISCO Pharmaceuticals GmbH, a Germany-based preclinical biotech, has appointed Mark Manfredi as chief executive officer. With 20 years’ experience in the biopharmaceutical industry and in cancer drug development, Dr Manfredi will oversee the advance and expansion of DISCO’s pipeline. In December, DISCO closed a €36 million seed financing round to advance multiple antibody-drug conjugate candidates in small cell lung cancer and microsatellite-stable colorectal cancer. Recently, Amgen Inc made a collaboration deal with DISCO which is potentially valued at $618 million plus royalties. Dr Manfredi succeeds DISCO’s founder and CEO Roman Thomas who will be a strategic advisor. Most recently he was CEO of Ikena Oncology, and previously was chief scientific officer of Raze Therapeutics and vice president, oncology biology at Takeda Pharmaceuticals. Dr Manfredi has a PhD in biology from Boston College, US.
DISCO Pharmaceuticals announced the appointment on 11 December 2025.
Copyright 2026 Evernow Publishing Ltd.